REVENUE MEMORANDUM CIRCULAR NO. 62-2025 issued on June 20, 2025 publishes the full text of the May 15, 2025 letter from Food and Drug Administration (FDA) Director General Paolo S. Teston endorsing updates to the List of VATExempt Products under Republic Act (RA) No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act).

The said List includes certain medicines for cancer, diabetes, high cholesterol, hypertension and mental diseases tuberculosis; and deletes certain medicine for cancer.

As clarified under Q&A No. 1 of RMC No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates on the said list.